AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38316738 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic approach
Number of subjects: 105
Study 38316738 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical time
Number of subjects: 105
Study 38316738 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical approach
Number of subjects: 105
Study 38316738 — intervention group
Group type: EXPERIMENTAL
Intervention: Charlson scale
Number of subjects: 105
Study 38316738 — intervention group
Group type: EXPERIMENTAL
Intervention: American Society of Anesthesiologists Classification
Number of subjects: 105
Study 38316982 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG 133 (maridebart cafraglutide)
Number of subjects: 0
Study 38316982 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38317120 — intervention group
Group type: EXPERIMENTAL
Intervention: Hair cortisol concentration (HCC) in clinical sample
Number of subjects: 91
Study 38317150 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving intervention for reducing sick leave among employees sick-listed due to common mental disorders.
Number of subjects: 27
Study 38317150 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 27
Study 38317178 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% albumin (12 mL/kg)
Number of subjects: 42
Study 38317178 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% albumin (3 mL/kg)
Number of subjects: 42
Study 38317178 — intervention group
Group type: COMPARATOR
Intervention: Ringer-lactate (3:1 ratio to replace blood loss)
Number of subjects: 42
Study 38317272 — intervention group
Group type: EXPERIMENTAL
Intervention: aXess Hemodialysis Graft
Number of subjects: 20
Study 38317375 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycine-powder air-polishing (GPAP)
Number of subjects: 52
Study 38317375 — intervention group
Group type: COMPARATOR
Intervention: Full-mouth ultrasonic debridement (Fm-UD)
Number of subjects: 52
Study 38317420 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous blinatumomab
Number of subjects: 0
Study 38317504 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant porcine factor VIII (rpFVIII) 1-2 hours before surgery
Number of subjects: 8
Study 38317504 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant porcine factor VIII (rpFVIII)
Number of subjects: 8
Study 38317618 — intervention group
Group type: EXPERIMENTAL
Intervention: Albiglutide
Number of subjects: 9462
Study 38318125 — intervention group
Group type: EXPERIMENTAL
Intervention: S48168 (ARM210) 120 mg daily for 29 days
Number of subjects: 7
Study 38318125 — intervention group
Group type: EXPERIMENTAL
Intervention: S48168 (ARM210) 200 mg daily for 29 days
Number of subjects: 7
Study 38318125 — intervention group
Group type: EXPERIMENTAL
Intervention: S48168 (ARM210)
Number of subjects: 7
Study 38318236 — intervention group
Group type: EXPERIMENTAL
Intervention: Efgartigimod (10 mg/kg infusion per week for 4 weeks)
Number of subjects: 151
Study 38318236 — intervention group
Group type: EXPERIMENTAL
Intervention: Efgartigimod
Number of subjects: 151
Study 38318270 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin (3000-7500 U for vascular surgery, 27,500-40,000 U for cardiac surgery)
Number of subjects: 3
Study 38318270 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (5000 U subcutaneously)
Number of subjects: 3
Study 38318270 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 3
Study 38318484 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.01% menthol solution
Number of subjects: 9
Study 38318484 — intervention group
Group type: COMPARATOR
Intervention: Placebo noncaloric solution
Number of subjects: 9
Study 38318645 — intervention group
Group type: EXPERIMENTAL
Intervention: TIPIC syndrome patients
Number of subjects: 28
Study 38318689 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacosamide
Number of subjects: 105
Study 38318689 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 38318703 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk Assessment Model (RAM) embedded in the electronic health record
Number of subjects: 26506
Study 38318703 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 26506
Study 38318773 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary care allied health treatment
Number of subjects: 30
Study 38318773 — intervention group
Group type: COMPARATOR
Intervention: Hospital participants
Number of subjects: 30
Study 38318773 — intervention group
Group type: COMPARATOR
Intervention: Home participants
Number of subjects: 30
Study 38318773 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal attention and support from primary care allied health professionals
Number of subjects: 30
Study 38318773 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment plan including physical exercise
Number of subjects: 30
Study 38318773 — intervention group
Group type: EXPERIMENTAL
Intervention: Listening to the patient’s story and offering support
Number of subjects: 30
Study 38318773 — intervention group
Group type: EXPERIMENTAL
Intervention: Interprofessional collaboration between primary care allied health professionals
Number of subjects: 30
Study 38318789 — intervention group
Group type: EXPERIMENTAL
Intervention: WHO case definition for COVID-19 diagnosis
Number of subjects: 971
Study 38318844 — intervention group
Group type: EXPERIMENTAL
Intervention: CYPWE
Number of subjects: 72
Study 38318844 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep-Related Breathing Disorder scale of the Pediatric Sleep Questionnaire
Number of subjects: 72
Study 38318844 — intervention group
Group type: COMPARATOR
Intervention: Typically developing controls
Number of subjects: 72
Study 38318960 — intervention group
Group type: EXPERIMENTAL
Intervention: 3RP-NF (Relaxation Response Resiliency Program for NF)
Number of subjects: 0
Study 38318960 — intervention group
Group type: COMPARATOR
Intervention: HEP-NF (Health Enhancement Program for NF)
Number of subjects: 0
Study 38319147 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-986351
Number of subjects: 0
Study 38319147 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-986351 combined with cetuximab and rituximab
Number of subjects: 0
Study 38319178 — intervention group
Group type: EXPERIMENTAL
Intervention: Molnupiravir 200 mg, 400 mg, or 800 mg, twice daily for 5 days
Number of subjects: 304
Study 38319178 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 304
Study 38319178 — intervention group
Group type: EXPERIMENTAL
Intervention: Molnupiravir (all doses combined)
Number of subjects: 304
Study 38319179 — intervention group
Group type: EXPERIMENTAL
Intervention: Molnupiravir (combined group of 200, 400, or 800 mg)
Number of subjects: 302
Study 38319179 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 302
Study 38319181 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery (partial meniscectomy or meniscal repair)
Number of subjects: 121
Study 38319181 — intervention group
Group type: COMPARATOR
Intervention: Exercise therapy and education (12-week supervised)
Number of subjects: 121
Study 38319181 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 121
Study 38319181 — intervention group
Group type: COMPARATOR
Intervention: Exercise therapy and education
Number of subjects: 121
Study 38319200 — intervention group
Group type: EXPERIMENTAL
Intervention: MV140 for 3 months
Number of subjects: 240
Study 38319200 — intervention group
Group type: EXPERIMENTAL
Intervention: MV140 for 6 months
Number of subjects: 240
Study 38319200 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 38319212 — intervention group
Group type: EXPERIMENTAL
Intervention: Ravulizumab
Number of subjects: 175
Study 38319212 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 175
Study 38319214 — intervention group
Group type: EXPERIMENTAL
Intervention: Bentracimab
Number of subjects: 150
Study 38319229 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart failure treatment
Number of subjects: 0
Study 38319239 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose subcutaneous aldesleukin (recombinant IL-2), 0.3 to 3.0 × 106 IU daily for 5 consecutive days (part A)
Number of subjects: 44
Study 38319239 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose subcutaneous aldesleukin (recombinant IL-2), 1.5 and 2.5 × 106 IU daily for 5 consecutive days (part B)
Number of subjects: 44
Study 38319239 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 38319241 — intervention group
Group type: EXPERIMENTAL
Intervention: Zilovertamab vedotin (ZV) at doses of 0.5, 1.0, 1.5, 2.25, and 2.5 mg/kg every 3 weeks until cancer progression or unacceptable toxicity.
Number of subjects: 32
Study 38319254 — intervention group
Group type: EXPERIMENTAL
Intervention: Reloxaliase
Number of subjects: 115
Study 38319254 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study 38319253 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose adeno-associated viral vector serotype 8 expressing ARSB
Number of subjects: 9
Study 38319253 — intervention group
Group type: EXPERIMENTAL
Intervention: Low and intermediate dose cohorts of adeno-associated viral vector serotype 8 expressing ARSB
Number of subjects: 9
Study 38319253 — intervention group
Group type: COMPARATOR
Intervention: Control group (ERT)
Number of subjects: 9
Study 38319255 — intervention group
Group type: EXPERIMENTAL
Intervention: ibrutinib-venetoclax
Number of subjects: 211
Study 38319255 — intervention group
Group type: COMPARATOR
Intervention: chlorambucil-obinutuzumab
Number of subjects: 211
Study 38319689 — intervention group
Group type: EXPERIMENTAL
Intervention: AMH cutoff of 3.2 ng/mL for the Elecsys AMH Plus or Elecsys AMH assays (Roche)
Number of subjects: 1803
Study 38319689 — intervention group
Group type: EXPERIMENTAL
Intervention: AMH measurement
Number of subjects: 1803
Study 38319698 — intervention group
Group type: EXPERIMENTAL
Intervention: Data Health program (intervention)
Number of subjects: 8
Study 38319800 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone (1000 mg once daily) plus olaparib (300 mg twice daily)
Number of subjects: 0
Study 38319800 — intervention group
Group type: COMPARATOR
Intervention: Abiraterone (1000 mg once daily) plus placebo
Number of subjects: 0
Study 38319800 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone and olaparib
Number of subjects: 0
Study 38319800 — intervention group
Group type: COMPARATOR
Intervention: Abiraterone and placebo
Number of subjects: 0
Study 38319800 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival data
Number of subjects: 0
Study 38319804 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab continuation
Number of subjects: 115
Study 38319804 — intervention group
Group type: COMPARATOR
Intervention: Infliximab discontinuation (placebo)
Number of subjects: 115
Study 38319812 — intervention group
Group type: EXPERIMENTAL
Intervention: Sabizabulin (9 mg orally daily for up to 21 days)
Number of subjects: 204
Study 38319812 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204
Study 38319832 — intervention group
Group type: EXPERIMENTAL
Intervention: sFlt-1:PlGF ratio ≥40
Number of subjects: 1014
Study 38319832 — intervention group
Group type: COMPARATOR
Intervention: sFlt-1:PlGF ratio <40
Number of subjects: 1014
Study 38319837 — intervention group
Group type: EXPERIMENTAL
Intervention: Decitabine (20 mg/m2 daily on days 1 to 3 every 28-day cycle)
Number of subjects: 113
Study 38319837 — intervention group
Group type: COMPARATOR
Intervention: Azacitidine (75 mg/m2 daily on days 1 to 3 every 28-day cycle)
Number of subjects: 113
Study 38319837 — intervention group
Group type: EXPERIMENTAL
Intervention: Decitabine (20 mg/m2 daily)
Number of subjects: 113
Study 38319837 — intervention group
Group type: COMPARATOR
Intervention: Azacitidine (75 mg/m2 daily)
Number of subjects: 113
Study 38319837 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall event-free survival
Number of subjects: 113
Study 38319837 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 113
Study 38319842 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 15 mg/day
Number of subjects: 111
Study 38319842 — intervention group
Group type: COMPARATOR
Intervention: No anticoagulation
Number of subjects: 111
Study 38319849 — intervention group
Group type: EXPERIMENTAL
Intervention: SNM ON
Number of subjects: 124
Study 38319849 — intervention group
Group type: COMPARATOR
Intervention: SNM OFF
Number of subjects: 124
Study 38319851 — intervention group
Group type: COMPARATOR
Intervention: PVI only
Number of subjects: 324
Study 38319851 — intervention group
Group type: EXPERIMENTAL
Intervention: PVI+SM
Number of subjects: 324
Study 38319850 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia at 33°C
Number of subjects: 2800
Study 38319850 — intervention group
Group type: COMPARATOR
Intervention: Normothermia
Number of subjects: 2800
Study 38319852 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (200 mg intravenously every 3 weeks for a total of 18 doses)
Number of subjects: 1019
Study 38319852 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1019
Study 38319865 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg
Number of subjects: 3425
Study 38319865 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3425
Study 38319878 — intervention group
Group type: EXPERIMENTAL
Intervention: Oteseconazole 150 mg orally daily for 7 days, then once weekly for 11 weeks
Number of subjects: 656
Study 38319878 — intervention group
Group type: EXPERIMENTAL
Intervention: Oteseconazole
Number of subjects: 656
Study 38319878 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 656
Study 38319878 — intervention group
Group type: EXPERIMENTAL
Intervention: Oteseconazole and Placebo
Number of subjects: 656
Study 38319892 — intervention group
Group type: EXPERIMENTAL
Intervention: STRIDE (tremelimumab 300 mg, one dose plus durvalumab 1500 mg every 4 weeks)
Number of subjects: 1171
Study 38319892 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab (1500 mg every 4 weeks)
Number of subjects: 1171
Study 38319892 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib (400 mg twice daily)
Number of subjects: 1171
Study 38319896 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab plus gemcitabine and cisplatin
Number of subjects: 685
Study 38319896 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus gemcitabine and cisplatin
Number of subjects: 685
Study 38319910 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional status assessment using bioelectrical impedance analysis (BIA) throughout multimodal treatment.
Number of subjects: 0
Study 38319937 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-wide mass drug administration (cMDA) for soil-transmitted helminths (STH)
Number of subjects: 0
Study 38320013 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia (33°C)
Number of subjects: 295
Study 38320013 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic normothermia (36.8°C)
Number of subjects: 295
Study 38320023 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab + Relatlimab (480 mg + 160 mg fixed-dose combination)
Number of subjects: 0
Study 38320023 — intervention group
Group type: COMPARATOR
Intervention: Nivolumab (480 mg alone)
Number of subjects: 0
Study 38320033 — intervention group
Group type: COMPARATOR
Intervention: Low-dose low-molecular-weight heparin thromboprophylaxis
Number of subjects: 1526
Study 38320033 — intervention group
Group type: COMPARATOR
Intervention: Intermediate-dose low-molecular-weight heparin thromboprophylaxis
Number of subjects: 1526
Study 38320033 — intervention group
Group type: COMPARATOR
Intervention: Low-dose plus aspirin
Number of subjects: 1526
Study 38320033 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic-dose anticoagulation
Number of subjects: 1526
Study 38320035 — intervention group
Group type: EXPERIMENTAL
Intervention: QIV-HD
Number of subjects: 12477
Study 38320035 — intervention group
Group type: COMPARATOR
Intervention: QIV-SD
Number of subjects: 12477
Study 38320051 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostatectomy
Number of subjects: 1643
Study 38320051 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy with neoadjuvant androgen deprivation
Number of subjects: 1643
Study 38320051 — intervention group
Group type: EXPERIMENTAL
Intervention: Active monitoring
Number of subjects: 1643
Study 38320088 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y reconstructive gastrectomy
Number of subjects: 531
Study 38320088 — intervention group
Group type: COMPARATOR
Intervention: Total gastrectomy
Number of subjects: 531
Study 38320088 — intervention group
Group type: COMPARATOR
Intervention: Distal gastrectomy
Number of subjects: 531
Study 38320088 — intervention group
Group type: EXPERIMENTAL
Intervention: Open surgery
Number of subjects: 531
Study 38320088 — intervention group
Group type: EXPERIMENTAL
Intervention: Females, BMI ≥23 kg/m2, No.12 lymph node dissection, adjuvant chemotherapy
Number of subjects: 531
Study 38320097 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased water intake (exact dosage and duration not specified)
Number of subjects: 0
Study 38320098 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia (33.0°C)
Number of subjects: 295
Study 38320098 — intervention group
Group type: COMPARATOR
Intervention: Normothermia (36.8°C)
Number of subjects: 295
Study 38320101 — intervention group
Group type: EXPERIMENTAL
Intervention: Microwave ablation (MWA)
Number of subjects: 672
Study 38320101 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic liver resection (LLR)
Number of subjects: 672
Study 38320106 — intervention group
Group type: EXPERIMENTAL
Intervention: Early THA
Number of subjects: 11731
Study 38320106 — intervention group
Group type: EXPERIMENTAL
Intervention: Early HA
Number of subjects: 11731
Study 38320126 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropeginterferon alfa-2b (ropeg; 100 μg every 2 weeks)
Number of subjects: 127
Study 38320126 — intervention group
Group type: COMPARATOR
Intervention: Phlebotomy only (standard therapy)
Number of subjects: 127
Study 38320127 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold static preservation at 10°C
Number of subjects: 70
Study 38320127 — intervention group
Group type: COMPARATOR
Intervention: Matched controls (standard preservation)
Number of subjects: 70
Study 38320128 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg daily
Number of subjects: 4304
Study 38320128 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4304
Study 38320129 — intervention group
Group type: EXPERIMENTAL
Intervention: Avapritinib 25 mg once daily
Number of subjects: 212
Study 38320129 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 212
Study 38320142 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (40 mg/day for 6 to 14 days)
Number of subjects: 2559
Study 38320142 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2559
Study 38320142 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 2559
Study 38320144 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalbuphine extended-release tablets (NAL ER) started at a dose of 27 mg once daily, titrated up to 162 mg twice daily at day 16.
Number of subjects: 41
Study 38320144 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalbuphine extended-release tablets (NAL ER)
Number of subjects: 41
Study 38320144 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 38320143 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT)
Number of subjects: 5727
Study 38320143 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 5727
Study 38320143 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy plus 4 months of ADT
Number of subjects: 5727
Study 38320155 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-month regimen of rifampicin at 1800 mg/d (SR2)
Number of subjects: 672
Study 38320155 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-month regimen of rifampicin at 1200 mg/d (SR1)
Number of subjects: 672
Study 38320155 — intervention group
Group type: COMPARATOR
Intervention: 6-month control regimen
Number of subjects: 672
Study 38320161 — intervention group
Group type: EXPERIMENTAL
Intervention: pegulicianine fluorescence-guided surgery (pFGS)
Number of subjects: 406
Study 38320162 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban 5 mg twice daily
Number of subjects: 863
Study 38320162 — intervention group
Group type: COMPARATOR
Intervention: Warfarin (target INR 2.0 to 3.0)
Number of subjects: 863
Study 38320162 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 863
Study 38320162 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 863
Study 38320163 — intervention group
Group type: EXPERIMENTAL
Intervention: 109-miRNA saliva diagnostic signature for endometriosis
Number of subjects: 200
Study 38320164 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with persistently detectable plasma EBV DNA
Number of subjects: 17838
Study 38320164 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with transiently positive plasma EBV DNA
Number of subjects: 17838
Study 38320164 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with persistently positive plasma EBV DNA
Number of subjects: 17838
Study 38320164 — intervention group
Group type: COMPARATOR
Intervention: Participants with undetectable plasma EBV DNA in the first round
Number of subjects: 17838
Study 38320181 — intervention group
Group type: EXPERIMENTAL
Intervention: Tezepelumab (210 mg every 4 weeks subcutaneously for at least 28 weeks)
Number of subjects: 82
Study 38320181 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 38320179 — intervention group
Group type: EXPERIMENTAL
Intervention: Vemurafenib 960 mg twice daily for four cycles plus obinutuzumab administered in cycles 2 to 4
Number of subjects: 30
Study 38320179 — intervention group
Group type: EXPERIMENTAL
Intervention: Vemurafenib plus obinutuzumab
Number of subjects: 30
Study 38320179 — intervention group
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Number of subjects: 30
Study 38320198 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (n=446)
Number of subjects: 917
Study 38320198 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n=471)
Number of subjects: 917
Study 38320207 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine
Number of subjects: 163